January 30, 2014
Novartis Pharma may have been involved in drafting the letter of consent issued to chronic myeloid leukemia (CML) patients before switching them to Tasigna (nilotinib) in the “Sign” trial, Jiho learned from several sources. According to sources, the company name...read more